Primed for at­tack: Vac­cine tech mak­er gets $11M shot to bat­tle in­fec­tious dis­ease

Tra­di­tion­al an­ti­body-based vac­cines, as a ba­sic prin­ci­ple, pre­vent in­fec­tion. UK-based Emergex’s tech­nol­o­gy doesn’t care if you do con­tract the in­fec­tion — it is en­gi­neered to en­sure you don’t fall sick.

Found­ed in 2016 by Uni­ver­si­ty Col­lege Lon­don (UCL) pro­fes­sor emer­i­tus of mol­e­c­u­lar med­i­cine and se­r­i­al en­tre­pre­neur Tom Rademach­er, the com­pa­ny Emergex on Thurs­day se­cured $11 mil­lion in Se­ries A fund­ing, led by Vick­ers Ven­ture Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER